Company Filing History:
Years Active: 2018-2022
Title: Kim Rosenthal: Innovator in Cancer Treatment
Introduction
Kim Rosenthal is a prominent inventor based in Gaithersburg, MD (US), known for her significant contributions to the field of cancer treatment. With a total of 4 patents, she has made remarkable strides in developing innovative therapies targeting CD73, a molecule associated with various cancers.
Latest Patents
One of Kim's latest patents is titled "Binding molecules specific for CD73 and uses thereof." This patent provides anti-CD73 binding molecules, including antibodies and their antigen-binding fragments. The disclosure also includes pharmaceutical formulations that comprise these compositions, along with methods for diagnosing and treating diseases linked to CD73 expression, such as cancer. The treatment options outlined in her patent include direct therapy using the anti-CD73 binding molecules, adjuvant therapy with other anticancer agents like immune checkpoint inhibitors, and combination therapies that involve administering anti-CD73 molecules alongside chemotherapy.
Career Highlights
Kim Rosenthal is currently employed at MedImmune Limited, where she continues to advance her research and development efforts in the biopharmaceutical sector. Her work focuses on creating innovative solutions for cancer treatment, leveraging her expertise in molecular biology and therapeutic development.
Collaborations
Throughout her career, Kim has collaborated with notable colleagues, including Carl Hay and Kris Sachsenmeier. These partnerships have contributed to her success in the field and have fostered a collaborative environment for innovation.
Conclusion
Kim Rosenthal's work exemplifies the impact of innovation in the medical field, particularly in cancer treatment. Her patents and ongoing research continue to pave the way for new therapeutic options that can significantly improve patient outcomes.